Major pathological response and durable locoregional control after neoadjuvant pembrolizumab-carboplatin-paclitaxel in head and neck cancer

Cabezas-Camarero, Santiago; Alonso-Ovies, Almudena; Merino-Menéndez, Salomé; Cabrera‐Martín, María Nieves; Plaza-Hernández, José Carlos; Pérez‐Segura, Pedro

doi:10.1016/j.oraloncology.2021.105589

Cited by 5 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, taxane-based dose-adapted chemo-IO combinations are promising alternatives for highly comorbid or ECOG ≥2 patients with R/M SCCHN who need a high and deep response rate (NCT04282109) (11,13). In the present series we aimed to retrospectively evaluate the safety and preliminary activity of pembrolizumab-carboplatin-paclitaxel (pembro + CP) in heavily pretreated R/M SCCHN.…”

Section: Introductionmentioning

confidence: 99%

“…In addition, the same combination is FDA- and EMA-approved in other squamous histologies such as CPS ≥1 first-line metastatic squamous cell non-small cell lung cancer (sqNSCLC) ( 12 ). In addition, taxane-based dose-adapted chemo-IO combinations are promising alternatives for highly comorbid or ECOG ≥2 patients with R/M SCCHN who need a high and deep response rate (NCT04282109) ( 11 , 13 ). In the present series we aimed to retrospectively evaluate the safety and preliminary activity of pembrolizumab-carboplatin-paclitaxel (pembro + CP) in heavily pretreated R/M SCCHN.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Safety and preliminary activity of pembrolizumab‑carboplatin‑paclitaxel in heavily pretreated and/or fragile patients with PDL1‑positive recurrent/metastatic head and neck cancer

et al. 2022

View full text Add to dashboard Cite

Novel chemo-immunotherapy (chemo-IO) combinations should be evaluated, which may be suitable for cisplatin-unfit or fluoropyrimide-ineligible patients with recurrent or metastatic squamous cell carcinoma of head and neck (R/M SCCHN) to guarantee higher and deeper responses than IO alone. The aim of the present study was to review our experience using pembrolizumab-carboplatin-paclitaxel (pembro + CP) in patients with R/M SCCHN. This was a retrospective study of patients with R/M SCCHN who received pembro + CP in any-line via a compassionate-use program. The present study evaluated safety using Common Terminology Criteria for Adverse Events v4.0, compliance, overall response rate (ORR) and disease control rate (DCR) using Response Evaluation Criteria in Solid Tumors 1.1, duration of treatment, progression-free survival (PFS) and overall survival (OS). Between March 2020 and August 2021, 10 patients were identified (median age, 64 years; female, 60%; Eastern Cooperative Oncology Group 2, 80%). A total of 8 patients received pembro + 3-weekly carboplatin-paclitaxel (3wkCP). A total of 2 patients received pembro + weekly carboplatin-paclitaxel (wkCP). Patients received a median of 3 lines (range, 0-6) of systemic therapy prior to pembro + CP and 80% received IO in previous lines. Grade 1-2 adverse events (AEs) occurred in 100% of patients. Grade 3-5 AEs occurred in 30% of patients [all grade 3 (anemia, neutropenia, thrombopenia, hypertension)]. The mean numbers of pembro + wkCP and pembro + 3wkCP cycles were 2.5 and 6. The ORR (n=7) was 14% (1/7) with one complete response. The DCR was 43% (3/7). The median PFS (n=7) and OS (n=10) times since pembro + CP were 5 months (95% CI, 1-9) and 6 months (95% CI, 0.5-14), respectively. In this small retrospective series of heavily pretreated patients, pembro + CP was well tolerated, and compliance was high. Studies should be conducted to prospectively evaluate the safety and efficacy of this combination in patients with R/M SCCHN.

show abstract

Section: Introductionmentioning

confidence: 99%